Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules. When tirzepatide is stopped, binge eating often returns, sometimes within weeks. The question of whether intranasal oxytocin can blunt this relapse sits at a tricky intersection of appetite neurobiology, stress adaptation, and female-specific hormonal signalling. Oxytocin modulates reward circuitry and dampens hypothalamic-pituitary-adrenal reactivity, both of which are implicated in post-GLP-1 weight regain. Yet the evidence linking oxytocin to binge eating prevention after tirzepatide discontinuation is largely indirect. This article examines what we would need to see to believe that claim, what data actually exist, and where the gaps remain, particularly for women.
What we'd want to see: the ideal evidence
To accept that intranasal oxytocin mitigates binge eating relapse after stopping tirzepatide, we would need a randomised, double-blind, placebo-controlled trial in women who had achieved weight loss on tirzepatide and then discontinued it. The primary endpoint would be binge eating frequency, measured by the Eating Disorder Examination (EDE) or a validated self-report tool, at something like 12 and 24 weeks post-tirzepatide. Ideally, the trial would include a crossover or parallel-group design with intranasal oxytocin (perhaps 24 IU twice daily, though optimal dosing is unknown) versus placebo, initiated at the time of tirzepatide cessation.
Secondary outcomes should capture hedonic eating, stress-induced eating, and weight regain. Neuroimaging data showing attenuated nucleus accumbens activation to food cues would strengthen a mechanistic narrative. We would also want to see stratification by menstrual cycle phase or menopausal status, given that oestrogen upregulates oxytocin receptor expression in the hypothalamus (Gimpl and Fahrenholz 2001). A trial of this kind does not exist, and the absence of such data defines the current uncertainty.
What we have: oxytocin, binge eating, and GLP-1s
Oxytocin's role in appetite and eating behaviour has been studied in small experimental settings. A meta-analysis of 11 studies found that intranasal oxytocin reduces caloric intake, particularly of palatable foods, with a moderate effect size (Leslie et al. 2019). In women with bulimia nervosa, a single 24 IU dose of intranasal oxytocin reduced attentional bias toward food images and lowered subjective urge to binge (Kim et al. 2015). However, these studies did not involve GLP-1 receptor agonists or weight-loss contexts.
On the binge eating side, a 2020 systematic review concluded that oxytocin administration may reduce binge eating frequency, but the evidence was limited to small samples and short follow-ups (Quintana et al. 2020). The largest trial to date, in 79 women with obesity and binge eating disorder, found that 24 IU intranasal oxytocin twice daily for 8 weeks did not significantly reduce binge eating episodes compared to placebo, though a post-hoc analysis suggested a benefit in those with higher baseline anxiety (Aulinas et al. 2022).
Regarding GLP-1 receptor agonists, tirzepatide and semaglutide suppress food intake partly through central mechanisms, including modulation of dopamine signalling in the nucleus accumbens (Gabery et al. 2020). When these drugs are stopped, rebound hyperphagia is common. In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo regained about 14% of lost weight over 52 weeks, while those continuing tirzepatide maintained losses (Aronne et al. 2023). No published study has examined oxytocin as a bridging therapy after GLP-1 discontinuation.
There is also preclinical work on BPC-157, a pentadecapeptide with putative healing properties, showing it can attenuate withdrawal-like behaviours in rodents after chronic amphetamine or diazepam exposure (Sikiric et al. 2018). Some have speculated about a role in appetite regulation, but human data are absent. Similarly, kisspeptin and PT-141 (bremelanotide) influence reproductive hormone axes and sexual function, respectively, with no direct evidence linking them to binge eating relapse after tirzepatide.
What's missing: the female neuroendocrine gap
Most oxytocin and binge eating studies have not controlled for menstrual cycle phase or menopausal status. This is a critical omission because oestradiol enhances oxytocin receptor binding in the ventromedial hypothalamus and amygdala (Gimpl and Fahrenholz 2001). In naturally cycling women, oxytocin's effects on stress reactivity and food reward may vary across the cycle. A 2021 study found that intranasal oxytocin reduced cortisol responses to a social stressor only during the luteal phase, when oestradiol and progesterone are elevated (Engert et al. 2021). Whether this translates to differential effects on stress-induced binge eating is unknown.
Furthermore, tirzepatide itself may alter menstrual regularity. GLP-1 receptor agonists can improve ovulatory function in polycystic ovary syndrome, but rapid weight loss can cause transient menstrual disturbances. One small series noted that 30% of women on semaglutide reported cycle changes (Jensterle et al. 2022). The interaction between tirzepatide-induced weight loss, subsequent menstrual changes, and oxytocin's cycle-dependent effects has not been explored. For women who experience binge eating relapse after stopping tirzepatide, the hormonal milieu at the time of discontinuation could influence whether oxytocin helps or does nothing.
Long-term safety data for intranasal oxytocin are also sparse. Most trials last 4 to 8 weeks. In the Aulinas et al. study, adverse events were mild (nasal irritation, headache), but the dropout rate was something like 15% in the oxytocin group. No study has followed women for 6 months or more, which would be necessary to assess sustained binge eating prevention after tirzepatide cessation.
How to read the existing signals
When interpreting the literature, it is helpful to distinguish between oxytocin's acute effects on appetite and its potential to prevent binge eating relapse over weeks. Acute reductions in food intake do not guarantee long-term binge eating control. The null result from the largest binge eating trial (Aulinas et al. 2022) tempers enthusiasm, though the post-hoc anxiety interaction suggests a subgroup might benefit. Women with high stress reactivity or emotional eating patterns could be more responsive, but this hypothesis needs prospective testing.
Another angle involves oxytocin's interaction with GLP-1 signalling. Preclinical data show that oxytocin neurons in the paraventricular nucleus express GLP-1 receptors, and GLP-1 analogues can stimulate oxytocin release (Rinaman 2010). After tirzepatide withdrawal, endogenous oxytocin tone might be altered, potentially creating a window where exogenous oxytocin is more or less effective. This has not been studied in humans. For those interested in related menstrual effects, oxytocin and semaglutide menstrual changes have been discussed elsewhere, highlighting the need for cycle-aware research.
The honest answer, with numbers
At present, there is no direct evidence that intranasal oxytocin mitigates binge eating relapse after stopping tirzepatide. The best available data suggest oxytocin can reduce acute food intake by something like 10-15% in laboratory settings, but its effect on binge eating episodes in clinical populations is inconsistent. The largest trial showed no overall benefit, with a mean difference of less than one binge episode per week between oxytocin and placebo (Aulinas et al. 2022). No study has tested oxytocin in the context of GLP-1 withdrawal, and no trial has lasted longer than 8 weeks. For women, the lack of menstrual cycle-controlled data is a major limitation, given oestradiol's influence on oxytocin receptor expression. While the neurobiology is plausible, the evidence gap is wide. Until a randomised trial addresses this specific question, the honest answer is that we do not know whether intranasal oxytocin can prevent binge eating relapse after tirzepatide discontinuation.